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Retrospective study on patients diagnosed with advanced 
Non-Small Cell Lung Cancer treated with the combination of 
gemcitabine and vinorelbine: assessment of therapeutic efficacy 
and prognosis factors
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Introduction: Gemcitabine (G), vinorelbine (V) and their combination 
(GV) have shown to be useful in patients with Non-Small Cell Lung 
Cancer (NSCLC). The purpose of this study has been to conﬁrm the 
effectiveness (activity) of GV and to identify prognostic factors related 
with clinical outcomes.
Methods: A retrospective analysis was carried out relating to 144 pa-
tients with NSCLC treated between October 1996 and April 2005 with 
G (1000-1250 mg/m2) +V (25-30 mg/m2) both administered on days 1 
and 8 every three weeks.
Results: Treatment was well tolerated neutropenia grade 3-4 being reg-
istered as the worse toxicity in 18% of cases, including 7% of neutrope-
nic fever. The objective response rate was 36.8% (95% CI: 28.9-44.7) 
and the median progression free survival and overall survival rates 
were 21 (18-25) and 33 (26-40) weeks respectively. In multivariate 
analysis only the histology of adenocarcinoma (HR 3; p<.0001), less 
than two metastatic sites (HR 1.7; p =.02)and Karnofsky index (KI) 
above 70 % (HR 1.5; p=.02) showed a signiﬁcant association with 
longer survival.
Conclusion: The combination of GV is well tolerated and active in 
patients with advanced NSCLC. The histology of adenocarcinoma, less 
than two metastatic sites and KI above 70 % have been identiﬁed as 
independent variables related with longer survival.
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Gemcitabine and vinorelbine combination as second-line therapy in 
previously taxane and platinum-treated non-small cell lung cancer
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Background: Gemcitabine (G) and vinorelbine (V) combination 
showed tolerable toxicities with response rate of 10-30% as second-line 
chemotherapy at several phase II studies. We evaluated its efﬁcacy and 
toxicity in previously taxane and platinum-treated refractory NSCLC. 
Methods: From July 2004 to February 2007, 25 evaluable patients 
were enrolled. All patients were refractory or resistant NSCLC after 
taxane and platinum combination as ﬁrst-line therapy for advanced 
NSCLC and ECOG PS 0-2. Treatment consisted of gemcitabine 1000 
mg/m2 plus vinorelbine 25 mg/m2 i.v. on days 1 & 8 of a 21-day cycle. 
Results: Among a total of 25 patients, 23 patients were evaluable for 
response and all 25 patients for toxicity. Median age was 58 years 
(range 44-79) and gender ratio was 19 males/6 females. Objective 
responses were seen in 5 of 23 evaluable patients (22%). four patients 
(18%) had stable disease and 14 patients (60%) progressive disease. 
Median overall survival was 5.3 months. A median of 2 cycles per 
patients were administered (range 1-8). The median delivered dose was 
538.5 mg/m2/week of gemcitabine and 13.3 mg/m2/week of vinorelbine 
and relative dose intensity was 81% and 80%, respectively. Grade 3/4 
neutropenia occurred in 68% but, febrile neutropenia only occurred in 
12%. Nausea, vomiting, anorexia, neuropathy and liver dysfunction 
were mild in most of patients. Grade 3 asthenia occurred in 20%. There 
was no predictive factor for tumor response of second-line therapy. For 
univariate analysis for overall survival, the responder of ﬁrst-line, good 
performance status, and disease-stabilized patients of GV chemothera-
py were signiﬁcantly analyzed (p<0.05). 
Conclusions: Gemcitabine and vinorelbine combination therapy 
showed modest efﬁcacy with disease stability of 40% and tolerable 
toxicity proﬁle in patients with previously taxane and platinum-treated 
refractory NSCLC. 
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Dose individualization of Carboplatin in elderly patients with 
advanced non small cell lung cancer (ANSCLC): an exploratory 
analysis
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Background: Application of population pharmacokinetic modelling 
to the routine therapeutic drug monitoring in elderly patients help to 
individualize the dosage of anticancer drugs. The aim of this study was 
to explore, by means of the individual pharmacokinetic parameters, 
the Calvert’s formula bias for establishing the Carboplatin (Cb) dose in 
elderly patients. Creatinine (Cr) Cl was calculated by Cockdroft-Gault 
equation.
Methods: Between December 2005 and September 2006, 19 chemona-
ive ANSCLC patients were included in two groups: 9 adult patients < 
65 years and 10 aged patients > 75 years. Treatment consisted in Cb 
day 1 and gemcitabine 1250 mg/m2 days 1 and 8 every 21 days. Cb 
dose was calculated for a foreseen AUC= 5 in young adults and AUC= 
4 in aged patients. Three blood samples were collected between 1-2 
hours (h), 3-5 h and 12-24 h post infusion. Ultraﬁltrated Carboplatin 
(Cbu) was determined using a ﬂameless atomic absorption spectrom-
eter. For pharmacokinetic analysis non lineal effects models imple-
mented in NONMEM program were used. Individual pharmacokinetic 
parameters were calculated and predictors in the structural model were 
analysed. 
Results: Mean and variation coefﬁcient of some biometric characteris-
tics and pharmacokinetic (PK) parameters are as follow:
 
Group
Cb  
Administered 
Dose (mg)
Age  
(years)
Cbu Cl 
Calvert 
(mL/min)
Cbu Cl 
Estimated 
(mL/min)
Cbu  
Calculated 
Dose (mg)
Young 662(23.4) 58(7.51) 129.62(25.2) 137(15.1) 741(19.9)
Elderly 323(16.1) 77.7(1.88) 81.61(8.21) 59.7(15.1) 234(20.9)
